Show simple item record

dc.contributor.authorBoland, M. R.
dc.contributor.authorMcVeigh, T. P.
dc.contributor.authorO'Flaherty, N.
dc.contributor.authorGullo, G.
dc.contributor.authorKeane, M.
dc.contributor.authorQuinn, C. M.
dc.contributor.authorMcDermott, E. W.
dc.contributor.authorLowery, A. J.
dc.contributor.authorKerin, M. J.
dc.contributor.authorPrichard, R. S.
dc.date.accessioned2017-08-25T11:16:25Z
dc.date.available2017-08-25T11:16:25Z
dc.date.issued2017-07-31
dc.identifier.citationImpact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy 2017 BJS Openen
dc.identifier.issn24749842
dc.identifier.doi10.1002/bjs5.6
dc.identifier.urihttp://hdl.handle.net/10147/622514
dc.description.abstractOptimal evaluation and management of the axilla following neoadjuvant chemotherapy(NAC) in patients with node-positive breast cancer remains controversial. The aim of this study wasto examine the impact of receptor phenotype in patients with nodal metastases who undergo NAC to seewhether this approach can identify those who may be suitable for conservative axillary management.Methods: Between 2009 and 2014, all patients with breast cancer and biopsy-proven nodal diseasewho received NAC were identied from prospectively developed databases. Details of patients who hadaxillary lymph node dissection (ALND) following NAC were recorded and rates of pathological completeresponse (pCR) were evaluated for receptor phenotype.
dc.language.isoenen
dc.publisherBSJ Openen
dc.relation.urlhttp://doi.wiley.com/10.1002/bjs5.6en
dc.rightsArchived with thanks to BJS Openen
dc.subjectBREAST CANCERen
dc.subjectCHEMOTHERAPYen
dc.titleImpact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapyen
dc.typeArticleen
dc.identifier.journalBJS Openen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
dc.contributor.institutionDepartment of Breast Surgery; St Vincent's University Hospital; Dublin Ireland
dc.contributor.institutionDepartment of Breast Surgery; University College Hospital Galway; Galway Ireland
dc.contributor.institutionDepartment of Breast Surgery; University College Hospital Galway; Galway Ireland
dc.contributor.institutionDepartment of Oncology; St Vincent's University Hospital; Dublin Ireland
dc.contributor.institutionDepartment of Oncology; University College Hospital Galway; Galway Ireland
dc.contributor.institutionDepartment of Pathology; St Vincent's University Hospital; Dublin Ireland
dc.contributor.institutionDepartment of Breast Surgery; St Vincent's University Hospital; Dublin Ireland
dc.contributor.institutionDepartment of Breast Surgery; University College Hospital Galway; Galway Ireland
dc.contributor.institutionDepartment of Breast Surgery; University College Hospital Galway; Galway Ireland
dc.contributor.institutionDepartment of Breast Surgery; St Vincent's University Hospital; Dublin Ireland
refterms.dateFOA2018-08-27T23:09:48Z
html.description.abstractOptimal evaluation and management of the axilla following neoadjuvant chemotherapy(NAC) in patients with node-positive breast cancer remains controversial. The aim of this study wasto examine the impact of receptor phenotype in patients with nodal metastases who undergo NAC to seewhether this approach can identify those who may be suitable for conservative axillary management.Methods: Between 2009 and 2014, all patients with breast cancer and biopsy-proven nodal diseasewho received NAC were identied from prospectively developed databases. Details of patients who hadaxillary lymph node dissection (ALND) following NAC were recorded and rates of pathological completeresponse (pCR) were evaluated for receptor phenotype.


Files in this item

Thumbnail
Name:
Boland_et_al-2017-BJS_Open.pdf
Size:
126.4Kb
Format:
PDF
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record